Citius Pharmaceuticals将通过股权发行筹集500万美元

2026-04-24 20:20

Citius Pharmaceuticals (CTXR) said it entered a definitive agreement to sell about 5.08M shares of common stock, or pre-funded warrants, at $0.985 per share in a registered direct offering priced at the market under Nasdaq rules.
In a concurrent private placement, the company will also issue warrants to buy up to 5.08M shares at an exercise price of $0.86 per share. The warrants will be exercisable immediately and expire five years after the related registration statement becomes effective.
The offering is expected to close on or about April 24, 2026, subject to customary closing conditions.
Gross proceeds from the offering are estimated to be around $5M. The firm will use. The net proceeds will support the commercial launch of Citius' immunotherapy LYMPHIR, as well as general corporate purposes.
CTXR shares down -15% premarket to $0.79.

More on Citius Pharmaceuticals